Results per Page:
When it comes to cancer trials, what’s the (end)point?
New endpoint in multiple myeloma could mean faster drug approvals. Are more endpoint tweaks on the way?
Once-weekly bortezomib is enough to treat multiple myeloma
From Dr. Rahul Banerjee, Clinical Research Division